Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and Chlamydia pneumoniae

Journal of Laboratory and Clinical Medicine

Volumn 144, Issue 1, 2004, Pages 18-26

  Bouwman, John J M ^a   Visseren, Frank L J ^b   Bouter, Paul K ^b   Diepersloot, Rob J A ^b  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b NONE

Author keywords

acute phase protein; acute phase reaction; analysis of variance; ANOVA; APP; APR; C reactive protein; CMV; CRP; cytomegalovirus; Earle's minimal essential medium; EMEM; FBS; fetal bovine serum; Hep; human epithelioma; IL; interleukin; lipoprotein A; Lp(a); MBC

Indexed keywords

AZITHROMYCIN; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG EFFECT; FIBRINOGEN SYNTHESIS; HUMAN; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; MEASUREMENT; TIME; TITRIMETRY; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL LINE, TUMOR; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; HEPATOCYTES; HUMANS; INTERLEUKIN-6; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 3142526240     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2004.03.012     Document Type: Article

References (54)

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 340:1999;115-126
2. Zhu J., Quyyumi A.A., Norman J.E., Csako G., Epstein S.E. Cytomegalovirus in the pathogenesis of atherosclerosis the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol. 34:1999;1738-1743
3. Mlot C. Chlamydia linked to atherosclerosis. Science. 272:1996;1422
4. Capron L. Role of infectious agents in the understanding of atherosclerosis. Rev Med Interne. 23:(suppl 1):2002;8s-9s
5. Visseren F.L., Bouwman J.J., Bouter K.P., Diepersloot R.J., de Groot P.H., Erkelens D.W. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost. 84:2000;319-324
6. Visseren F.L., Verkerk M.S., Bouter K.P., Diepersloot R.J., Erkelens D.W. Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. J Lab Clin Med. 134:1999;623-630
7. Verkerk M.S., Visseren F.L., Bouter K.P., Diepersloot R.J. Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus. Eur J Clin Invest. 33:2003;720-725
8. Darlington G.J., Wilson D.R., Revel M., Kelly J.H. Response of liver genes to acute phase mediators. [discussion] Ann N Y Acad Sci. 557:1989;310-315
9. Ceciliani F., Giordano A., Spagnolo V. The systemic reaction during inflammation the acute-phase proteins. Protein Pept Lett. 9:2002;211-223
10. Baumann H., Gauldie J. The acute phase response. Immunol Today. 15:1994;74-80
11. Fey G.H., Gauldie J. The acute phase response of the liver in inflammation. Prog Liver Dis. 9:1990;89-116
12. Vasse M., Paysant J., Soria J., Collet J.P., Vannier J.P., Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis. 26:(suppl 4):1996;331-339
13. Vasse M., Paysant I., Soria J., Mirshahi S.S., Vannier J.P., Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 93:1996;955-961
14. Niessen R.W., Lamping R.J., Jansen P.M., Prins M.H., Peters M., Taylor F.B. Jr, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost. 78:1997;1088-1092
15. Gabay C., Porter B., Guenette D., Billir B., Arend W.P. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells differential effect on C-reactive protein production. Blood. 93:1999;1299-1307
16. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 101:1998;311-320
17. Gauldie J., Richards C., Baumann H. IL6 and the acute phase reaction. Res Immunol. 143:1992;755-759
18. Richards C, Gauldie J, Baumann H. Cytokine control of acute phase protein expression. Eur Cytokine Netw 1991;2:89-98
19. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 265:1990;621-636
20. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6 from basic science to medicine. Arthr Res. 4:(suppl 3):2002;S233-242
21. Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol. 115:2001;3-12
22. Luc G., Bard J.M., Juhan-Vague I., Ferrieres J., Evans A., Amonyel P., et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease the PRIME study. Arterioscler Thromb Vasc Biol. 23:2003;1255-1261
23. Bouwman J.J., Visseren F.L., Bosch M.C., Bouter K.P., Diepersloot R.J. Procoagulant and inflammatory response of virus-infected monocytes. Eur J Clin Invest. 32:2002;759-766
24. Dechend R., Maass M., Gieffers J., Dietz R., Scheidereid C., Lentz A., et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression a potential link to accelerated arteriosclerosis. Circulation. 100:1999;1369-1373
25. Rodel J, Woytas M, Groh A, Schmidt KH, Hartmann M, Lehmann M, et al. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 2000;68:3635-41
26. Lupu F., Bergonzelli G.E., Heim D.A., Cousin E., Genton C.Y., Bachmann F., et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 13:1993;1090-1100
27. Healy A.M., Gelehrter T.D. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem. 269:1994;19095-19100
28. Ballow C.H., Amsden G.W. Azithromycin the first azalide antibiotic. Ann Pharmacother. 26:1992;1253-1261
29. Peters D.H., Friedel H.A., McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 44:1992;750-799
30. Van Bambeke F., Tulkens P.M. Macrolides pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 18:(suppl 1):2001;S17-23
31. Ianaro A., Ialenti A., Maffia P., Sautebin L., Rombola L., Carnuccio R., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 292:2000;156-163
32. Scaglione F., Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother. 41:(suppl B):1998;47-50
33. Muhlestein J.B., Anderson J.L., Hammond E.H., Zhao L., Trehan S., Schwobe E.P., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636
34. Muhlestein J.B. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis. 181:(suppl 3):2000;S505-507
35. Uriarte S.M., Molestina R.E., Miller R.D., Bernabo J., Farinati A., Eiguchi K., et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis. 185:2002;1631-1636
36. Culic O., Erakovic V., Cepelak I., Barisic F., Brajsa K., Ferencic Z., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 450:2002;277-289
37. Parchure N., Zouridakis E.G., Kaski J.C. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 105:2002;1298-1303
38. Northemann W., Hattori M., Baffet G., Braciak T.A., Fletcher R.G., Abraham L.J., et al. Production of interleukin 6 by hepatoma cells. Mol Biol Med. 7:1990;273-285
39. Lotz M., Zuraw B.L., Carson D.A., Jirik F.R. Hepatocytes produce interleukin-6. Ann N Y Acad Sci. 557:1989;509-511
40. Zuraw B.L., Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte-stimulating factors interleukin 6 and interferon gamma. J Biol Chem. 265:1990;12664
41. Paysant J., Blanque R., Vasse M., Soria C., Soria J., Gardner C.R. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Cytokine. 12:2000;774-779
42. Campbell L.A., Kuo C.C. Chlamydial infections of the cardiovascular system. Front Biosci. 8:2003;e36-362143
43. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407
44. Dunne M.W. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction the WIZARD (Weekly Intervention with Zithromax [azithromycin] for Atherosclerosis and its Related Disorders) trial. J Infect Dis. 181:(suppl 3):2000;S572-578
45. Jackson L.A. Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis. 181:(suppl 3):2000;S579-581
46. Cercek B., Shah P.K., Noc M., Zagher D., Zeymer U., Matetsky S., et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial a randomised controlled trial. Lancet. 361:2003;809-813
47. Anderson J.L., Muhlestein J.B., Carlquist J., Allen A., Trehan S., Nielson C., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 99:1999;1540-1547
48. Rothstein N.M., Quinn T.C., Madico G., Gaydos C.A., Lowenstein C.J. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis. 183:2001;232-238
49. Gurfinkel E., Bozovich G., Beck E., Testa E., Livellara B., Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J. 20:1999;121-127
50. Zahn R., Schneider S., Frilling B., Zeidl K., Tebbe U., Weber M., et al. Antibiotic therapy after acute myocardial infarction a prospective randomized study. Circulation. 107:2003;1253-1259
51. Wiesli P., Czerwenka W., Meniconi A., Maly F.E., Hoffmann U., Vetter W., et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae-seropositive men a randomized, double-blind, placebo-controlled trial. Circulation. 105:2002;2646-2652
52. Grayston J.T. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation. 107:2003;1228-1230
53. Gieffers J., Fullgraf H., Jahn J., Flinger M., Dahlhoff K., Fatus H.A., et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 103:2001;351-356
54. Gelfand E.V., Cannon C.P. Antibiotics for secondary prevention of coronary artery disease An ACES hypothesis but we need to PROVE IT. Am Heart J. 147:2004;202-209